News

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

Neda Shamie, MD, previews the May 4 conference, where a faculty of ophthalmologists and optometrists will explore the latest advancements and controversies.

Celebrating a half-century of progress with Ophthalmology Times.

The annual ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening the dosing schedule to include every-4-week dosing across approved indications.

Updated guidelines characterize IOLs by functional performance over optical design.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there currently are no approved treatments.

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts in the Qassim region of Saudi Arabia.

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Eyecyte-RPE is a suspension of human induced pluripotent stem cell–derived retinal pigment epithelial cells.

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.

In their study, 16 ophthalmologists, including attending physicians and residents with levels of experience ranging from 1 to 9 years, were included.

The partnership will integrate Ocuco’s optical software solution, Acuitas 3, with Nextech’s Ophthalmic Platform.

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

Personalizing treatment options and setting realistic expectations are crucial.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.